Skip to main content
PMC home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1988 Sep;27(2):154–162. doi: 10.1007/BF00200021

Immunohistochemical monitoring of metastatic colorectal carcinoma in patients treated with monoclonal antibodies (MAb 17-1A)

Jayant Shetye 1,2, Jan-Erik Frödin 2, Birger Christensson 1, Crawford Grant 1, Björn Jacobsson 1, Staffan Sundelius 3, Mikael Sylvén 3, Peter Biberfeld 1, H»kan Mellstedt 2,✉
PMCID: PMC11038272  PMID: 3262013

Abstract

A therapeutic trial using repeated doses of a mouse monoclonal antibody against the tumor-associated antigen (TAA) CO17-1A in metastatic colorectal carcinomas was carried out. Metastatic lesions sampled by repeated thick needle (1.2 mm) biopsies during therapy were examined immunohistochemically for the presence of various TAAs, mouse IgG, complement, and infiltrating leukocytes. The CO17-1A was consistently expressed in all cases along the basement membrane of tumor glands and could only be demonstrated on cryostat sections whereas the TAAs GICA19-9, GA73-3, and Br55-2 were also visualized in B5-fixed paraffin-embedded biopsies. The CO17-1A and GA73-3 were predominantly present at the basal region in contrast to the GICA 19-9 and Br55-2 which were predominant at the luminal and the apical region of the tumor glands. Antigenic modulation was not seen either after 24–72 h or during prolonged treatment. In all cases the infused mouse IgG was detected, from 24 h after infusion up to 6–8 weeks, mainly along the basal region of tumor glands. In 13/14 posttreatment biopsies, complement factor C3 was found at the same sites as mouse IgG. In 6 out of 9 posttreatment biopsies an increase in mononuclear cells (monocytes, natural killer (NK) cells and/or T cells) was observed. Monocytes were close to the tumor cells whereas NK cells and T cells were predominantly scattered in the stroma.

Keywords: Natural Killer, Luminal, Natural Killer Cell, Mouse Monoclonal Antibody, Metastatic Lesion

Footnotes

This study was supported by grants from the Cancer Society in Stockholm, the King Gustav Vth Jubilee Fund, The Swedish Cancer Society and the Karolinska Institute Foundations

References

  • 1.Adams DO, Hall T, Steplewski Z, Koprowski H. Tumors undergoing rejection induced by monoclonal antibodies of the IgG2a isotype contain increased numbers of macrophages activated for a distinctive form of antibody-dependent cytolysis. Proc Natl Acad Sci. 1984;81:3506. doi: 10.1073/pnas.81.11.3506. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Bedikian AY, Chen TT, Malahy MA, Patt YZ, Bodey GP. Prognostic factors influencing survival of patients with advanced colorectal cancer: Hepatic artery infusion versus systemic intravenous chemotherapy for liver metastases. J Clin Oncol. 1984;2:174. doi: 10.1200/JCO.1984.2.3.174. [DOI] [PubMed] [Google Scholar]
  • 3.Bergmark S, Hagfström LO. The natural history of primary and secondary malignant tumors of the liver. I. The prognosis for patients with hepatic metastases from colonic and rectal carcinoma by laparotomy. Cancer. 1969;23:198. doi: 10.1002/1097-0142(196901)23:1<198::aid-cncr2820230126>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  • 4.Dawson PM, Habib NA, Peck M, Blaxland JW, Luck RJ. Patient survival with liver metastases from colorectal cancer — a district hospital experience. Eur J Surg Oncol. 1986;12:131. [PubMed] [Google Scholar]
  • 5.Douillard JY, Lehur PA, Vignoud J, Blottiere H, Maurel C, Thedrez P, Kremer M, Le Mevel B. Monoclonal antibodies specific immunotherapy of gastro-intestinal tumors. Hybridoma. 1986;5(I):139. [PubMed] [Google Scholar]
  • 6.Dukes CE, Bussey HJR. The spread of rectal cancer and its effects on prognosis. Br J Cancer. 1958;12:309. doi: 10.1038/bjc.1958.37. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Ekberg H, Tranberg KG, Lundstedt C, Hahff G, Ranstam J, Jeppsson B, Bengmark S. Determinants of survival after intraarterial infusion of 5-fluorouracil for liver metastases from colorectal cancer: A multivariate analysis. J Surg Oncol. 1986;31:246. doi: 10.1002/jso.2930310406. [DOI] [PubMed] [Google Scholar]
  • 8.Frödin JE, Biberfeld P, Christensson B, Philstedt P, Sundelius S, Sylvén M, Wahren B, Koprowski H, Mellstedt H. Treatment of patients with metastasizing colo-rectal carcinoma with mouse monoclonal antibodies (MOAb17-1A). A progress report. Hybridoma. 1986;5(I):151. [PubMed] [Google Scholar]
  • 9.Garcia CF, Lowder J, Meeker TC, Bindl J, Levy R, Warnke RA. Differences in “host infiltrates” among lymphoma patients treated with anti-idiotype antibodies: correlation with treatment response. J Immunol. 1985;135:4252. [PubMed] [Google Scholar]
  • 10.Goslin R, Steele G, Jr, Zamcheck N, Mayer R, MacIntyre J. Factors influencing survival in patients with hepatic metastases from adenocarcinoma of the colon or rectum. Dis Colon Rectum. 1982;25:749. doi: 10.1007/BF02553304. [DOI] [PubMed] [Google Scholar]
  • 11.Herlyn DM, Koprowski H. IgG2A monoclonal antibodies inhibit human tumor growth through interaction with effector cells. Proc Natl Acad Sci. 1982;79:4761. doi: 10.1073/pnas.79.15.4761. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Herlyn DM, Herlyn MF, Steplewski Z, Koprowski H. Monoclonal antibodies in cell-mediated cytotoxicity against human melanoma and colo-rectal carcinoma. Eur J Immunol. 1979;9:657. doi: 10.1002/eji.1830090817. [DOI] [PubMed] [Google Scholar]
  • 13.Herlyn DM, Herlyn MF, Ross AH, Ernst C, Atkinson B, Koprowski H. Efficient selection of human tumor growth-inhibiting monoclonal antibodies. J Immunol Methods. 1984;73:157. doi: 10.1016/0022-1759(84)90041-3. [DOI] [PubMed] [Google Scholar]
  • 14.Herlyn MF, Steplewski Z, Herlyn DM, Koprowski H. CO17-1A and related monoclonal antibodies: Their production and characterization. Hybridoma. 1986;5(I):3. [PubMed] [Google Scholar]
  • 15.Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase Complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabelled antibody (PAP) procedures. J Histochem Cytochem. 1981;29:577. doi: 10.1177/29.4.6166661. [DOI] [PubMed] [Google Scholar]
  • 16.Magnani JL, Nilson B, Brockhaus M, Zopf D, Steplewski Z, Koprowski H, Ginsburg V. A monoclonal antibody defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentaose II. J Biol Chem. 1982;257:14365. [PubMed] [Google Scholar]
  • 17.Mason DY, Bell JJ, Christensson B, Biberfeld P. An immunohistological study of human lymphoma. Clin Exp Immunol. 1980;40:235. [PMC free article] [PubMed] [Google Scholar]
  • 18.Mellstedt H, Frödin J-E, Christensson B, Shetye J, Biberfeld P, Lefvert A-K, Pihlstedt P, Sylvén M, Makower J, Wahren B, Ahlman B, Cedermark B, Erwald R, Klingenström P, Nathansson J, Rieger A, Koprowski H. Application of monoclonal antibodies (MAb 17-1A) in the treatment of colorectal carcinomas. In: Carrano RA, Douillard JY, editors. Monoclonal antibodies in clinical oncology. New York: Marcel Dekker; 1988. [Google Scholar]
  • 19.Mellstedt H, Frödin J-E, Masucci G, Lindemalm C, Wedelin C, Christensson B, Shetye J, Biberfeld P, Lefvert A-K, Pihlstedt P, Makower J, Harmenberg U, Wahren B, Ahlman B, Cedermark B, Erwald R, Magnusson I, Nathansson J, Rieger A. MAb 17-1A used for therapy of patients with metastatic colorectal carcinomas. In: Beger HG, Reisfeld R, editors. New approaches in cancer treatment. Berlin: Springer-Verlag; 1988. [Google Scholar]
  • 20.Neville AM, Gusterson BA. Monoclonal antibodies and human tumors; pathological and clinical aspects. Eur J Cancer Clin Oncol. 1985;21:355. doi: 10.1016/0277-5379(85)90136-1. [DOI] [PubMed] [Google Scholar]
  • 21.Porwit-Ksiazek A, Ksiazek T, Biberfeld P. Leu-7+ (HNK-1+) cells. I. Selective compartmentalisation of Leu-7+ cells with different immunophenotypes in lymphatic tissues and blood. Scand J Immunol. 1983;18:485. doi: 10.1111/j.1365-3083.1983.tb00882.x. [DOI] [PubMed] [Google Scholar]
  • 22.Ross AH, Herlyn D, Diopoulos D, Koprowski H. Isolation and characterization of a carcinoma-associated antigen. Biochem Biophys Res Commun. 1986;135:297. doi: 10.1016/0006-291x(86)90976-9. [DOI] [PubMed] [Google Scholar]
  • 23.Schulz G, Staffileno LK, Reisfeld RA, Dennert G. Eradication of established human melanoma tumor in nude mice by antibody-directed effector cells. J Exp Med. 1985;161:1315. doi: 10.1084/jem.161.6.1315. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Sears HF, Mattis J, Herlyn DM, Häyry P, Atkinson B, Ernst C, Steplewski Z, Koprowski H. Phase I clinical trial of monoclonal antibody in treatment of gastro-intestinal tumors. Lancet. 1982;I:762. doi: 10.1016/s0140-6736(82)91811-6. [DOI] [PubMed] [Google Scholar]
  • 25.Sears HF, Herlyn DM, Häyry P, Atkinson B, Ernst C, Steplewski Z, Koprowski H. Phase II clinical trial of a murine monoclonal antibody cytotoxic for gastro-intestinal adenocarcinoma. Cancer Res. 1985;45:5910. [PubMed] [Google Scholar]
  • 26.Sears HF, Herlyn DM, Steplewski Z, Koprowski H. Initial trial use of murine monoclonal antibodies as immunotherapeutic agents for gastro-intestinal adenocarcinoma. Hybridoma. 1986;5(I):109. [PubMed] [Google Scholar]
  • 27.Shen JW, Atkinson B, Koprowski H, Sears HF. Binding of murine immunoglobulin to human tissues after immunotherapy with anti-colo-rectal carcinoma monoclonal antibody. Int J Cancer. 1984;33:465. doi: 10.1002/ijc.2910330408. [DOI] [PubMed] [Google Scholar]
  • 28.Sindelar WF, Maher MM, Herlyn D, Sears HF, Steplewski Z, Koprowski H. Trial of therapy with monoclonal antibody 17-1A in pancreatic carcinoma. Preliminary results. Hybridoma. 1986;5(I):125. [PubMed] [Google Scholar]
  • 29.Steplewski Z, Herlyn D, Lubeck M, Kimoto Y, Herlyn M, Koprowski H. Mechanisms of tumor growth inhibition. Hybridoma. 1986;5(I):59. [PubMed] [Google Scholar]
  • 30.Tempero MA, Pour PM, Uchida E, Herlyn D, Steplewski Z. Monoclonal antibody CO17-1A and leukapheresis in immunotherapy of pancreatic cancer. Hybridoma. 1986;5(I):133. [PubMed] [Google Scholar]
  • 31.Blaszczyk-Thurin M, Thurin J, Hindsgaul O, Karlsson KA, Steplewski Z, Koprowski H. Y and blood group B type 2 glycolipid antigens accumulate in a human gastric carcinoma cell line as detected by monoclonal antibody: Isolation and characterization by mass spectrometry and NMR spectroscopy. J Biol Chem. 1987;262(1):372. [PubMed] [Google Scholar]
  • 32.Verrill H, Goldberg M, Rosenbaum R, Abbott R, Simunovic L, Steplewski Z, Koprowski H. Clinical trial of Wistar Institute 17-1A monoclonal antibody in patients with advanced gastro-intestinal adenocarcinoma. A preliminary report. Hybridoma. 1986;5(I):175. [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES